<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mannitol (oral inhalation): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mannitol (oral inhalation): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mannitol (oral inhalation): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="109077" href="/d/html/109077.html" rel="external">see "Mannitol (oral inhalation): Drug information"</a> and <a class="drug drug_patient" data-topicid="108770" href="/d/html/108770.html" rel="external">see "Mannitol (oral inhalation): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F28661985"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of severe bronchospasm (Aridol):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mannitol acts as a bronchoconstrictor and may cause severe bronchospasm. Bronchial challenge testing with mannitol is for diagnostic purposes only. Bronchial challenge testing with mannitol should only be conducted by trained professionals under the supervision of a health care provider familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (eg, short-acting inhaled beta-agonists) and equipment to treat severe bronchospasm must be present in the testing area. If severe bronchospasm occurs, it should be treated immediately by administration of a short-acting inhaled beta-agonist. Because of the potential for severe bronchoconstriction, the bronchial challenge testing with mannitol should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (eg, forced expiratory volume at 1 second [FEV<sub>1</sub>] less than 1 to 1.5 L or less than 70% of the predicted values).</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53669403"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aridol;</li>
<li>Bronchitol;</li>
<li>Bronchitol Tolerance Test</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54882624"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Aridol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F28673446"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Diagnostic Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F28662039"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6cdd4764-692a-406a-848c-f5ee5e0ad7d6">Bronchial hyper-responsiveness assessment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchial hyper-responsiveness assessment:</b> Aridol: Children ≥6 years and Adolescents: Oral inhalation: Dry powder inhaler (capsule): Administer in a stepwise fashion (measuring FEV<sub>1</sub> in duplicate at baseline and after each administration) until the patient has a positive response or 635 mg of mannitol has been administered (whichever comes first).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Positive test:</i> 15% reduction in FEV<sub>1</sub> from baseline or 10% incremental reduction in FEV<sub>1</sub> between consecutive doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Negative test:</i> Administration of full dose (635 mg) without reduction in FEV<sub>1</sub> sufficient to meet criteria for a positive test.</p>
<p style="text-indent:-2em;margin-left:4em;">Administration should be as follows:</p>
<table border="1" data-table-id="aridol" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Stepwise Administration Schedule</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Dose #</p></th>
<th align="center">
<p style="text-indent:0em;">Dose (mg)</p></th>
<th align="center">
<p style="text-indent:0em;">Cumulative Dose (mg)</p></th>
<th align="center">
<p style="text-indent:0em;">Capsules/Dose</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">1</p></td>
<td align="center">
<p style="text-indent:0em;">0</p></td>
<td align="center">
<p style="text-indent:0em;">0</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2</p></td>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">15</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">35</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">75</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="center">
<p style="text-indent:0em;">80</p></td>
<td align="center">
<p style="text-indent:0em;">155</p></td>
<td align="center">
<p style="text-indent:0em;">2 x 40 mg caps</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">7</p></td>
<td align="center">
<p style="text-indent:0em;">160</p></td>
<td align="center">
<p style="text-indent:0em;">315</p></td>
<td align="center">
<p style="text-indent:0em;">4 x 40 mg caps</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8</p></td>
<td align="center">
<p style="text-indent:0em;">160</p></td>
<td align="center">
<p style="text-indent:0em;">475</p></td>
<td align="center">
<p style="text-indent:0em;">4 x 40 mg caps</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">9</p></td>
<td align="center">
<p style="text-indent:0em;">160</p></td>
<td align="center">
<p style="text-indent:0em;">635</p></td>
<td align="center">
<p style="text-indent:0em;">4 x 40 mg caps</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fbc98cc2-7229-45fb-ac1a-8fb1c8443c5e">Cystic fibrosis, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis (CF), maintenance: </b>Bronchitol:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use only in patients who have passed the Bronchitol tolerance test (BTT); refer to manufacturer labeling for detailed instructions on BTT administration. Administer a short-acting bronchodilator 5 to 15 minutes before every dose. If bronchospasm occurs at any point, discontinue immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;18 years: Limited data available: Oral inhalation: Dry powder inhaler (capsule): 400 mg (contents of 10 capsules) inhaled twice daily. Dosing based on a randomized, placebo-controlled crossover trial in patients with CF (n=92; mean age: 12 ± 3 years; range: 6 to 17 years); after 8 weeks of treatment, results showed mannitol showed significant improvement in lung function and pulmonary exacerbations were decreased (De Boek 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Oral inhalation: Dry powder inhaler (capsule): 400 mg (contents of 10 capsules) twice daily (morning and evening), with the later dose taken 2 to 3 hours before bedtime.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130172"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, drug is primarily renally eliminated and systemic exposure may be increased; use with caution in patients with underlying renal disease.</p></div>
<div class="block dohp drugH1Div" id="F51130173"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No adjustment required.</p></div>
<div class="block doa drugH1Div" id="F28662040"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="109077" href="/d/html/109077.html" rel="external">see "Mannitol (oral inhalation): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abf8e30f-f3bc-4c03-91b6-3d1e0679900e">Assessment of bronchial hyperresponsiveness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Assessment of bronchial hyperresponsiveness (Aridol): Oral inhalation:</b> Dry powder inhaler (capsule): Administer in a stepwise fashion (measuring FEV<sub>1</sub> in duplicate after each administration) until the patient has a positive response or 635 mg of mannitol has been administered (whichever comes first).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Positive test:</i> 15% reduction in FEV<sub>1</sub> from baseline or 10% incremental reduction in FEV<sub>1</sub> between consecutive doses</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Negative test:</i> Administration of full dose (635 mg) without reduction in FEV<sub>1</sub> sufficient to meet criteria for a positive test</p>
<p style="text-indent:-2em;margin-left:4em;">Administration should be as follows:</p>
<table border="1" data-table-id="aridol" frame="border" rules="all">
<caption style="text-align:center;">
<b>Stepwise Administration Schedule</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Dose #</p></th>
<th align="center">
<p style="text-indent:0em;">Dose (mg)</p></th>
<th align="center">
<p style="text-indent:0em;">Cumulative Dose (mg)</p></th>
<th align="center">
<p style="text-indent:0em;">Capsules/Dose</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">1</p></td>
<td align="center">
<p style="text-indent:0em;">0</p></td>
<td align="center">
<p style="text-indent:0em;">0</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2</p></td>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">15</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">35</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">75</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="center">
<p style="text-indent:0em;">80</p></td>
<td align="center">
<p style="text-indent:0em;">155</p></td>
<td align="center">
<p style="text-indent:0em;">2 x 40 mg caps</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">7</p></td>
<td align="center">
<p style="text-indent:0em;">160</p></td>
<td align="center">
<p style="text-indent:0em;">315</p></td>
<td align="center">
<p style="text-indent:0em;">4 x 40 mg caps</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8</p></td>
<td align="center">
<p style="text-indent:0em;">160</p></td>
<td align="center">
<p style="text-indent:0em;">475</p></td>
<td align="center">
<p style="text-indent:0em;">4 x 40 mg caps</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">9</p></td>
<td align="center">
<p style="text-indent:0em;">160</p></td>
<td align="center">
<p style="text-indent:0em;">635</p></td>
<td align="center">
<p style="text-indent:0em;">4 x 40 mg caps</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fbc98cc2-7229-45fb-ac1a-8fb1c8443c5e">Cystic fibrosis, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, maintenance (Bronchitol):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use only in patients who have passed the Bronchitol tolerance test; if bronchospasm occurs, discontinue immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral inhalation:</b> Dry powder inhaler (capsule): 400 mg inhaled (contents of 10 capsules) twice a day (morning and evening), with the later dose taken 2 to 3 hours before bedtime; administer a short-acting bronchodilator 5 to 15 minutes before every dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992050"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, drug is primarily renally eliminated and systemic exposure may be increased; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50989351"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F28662011"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Diagnostic Agent:</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Chest discomfort (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea (2% to 3%), retching (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness (1%), headache (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (2%), dyspnea (1%), pharyngolaryngeal pain (2% to 4%), rhinorrhea (2%), throat irritation (2%), wheezing (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Cystic fibrosis:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Respiratory: Cough (15%), exacerbation of pulmonary disease (exacerbation of cystic fibrosis, can be serious: 13% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Hemoptysis (10%), increased bronchial sections (bacterial: 7%), oropharyngeal pain (7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all indications): Respiratory: Bronchospasm, reduced forced expiratory volume</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all indications): Gastrointestinal: Gag reflex</p></div>
<div class="block coi drugH1Div" id="F28662008"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mannitol, gelatin, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Aridol</b>: Conditions that may be compromised by induced bronchospasm or repeated spirometry maneuvers (eg, aortic or cerebral aneurysm, uncontrolled hypertension, recent myocardial infarction or cerebral vascular accident).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchitol</b>: Failure to pass the Bronchitol tolerance test.</p></div>
<div class="block war drugH1Div" id="F28662009"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:2em;">• Bronchospasm: <b>Aridol: </b>
<b>[US Boxed Warning] Use may result in severe bronchospasm; use only for bronchial challenge testing. Testing should only be done by trained professionals. Not for use in patients with asthma or very low baseline pulmonary function (eg, FEV<sub>1</sub> &lt;1 to 1.5 L or &lt;70% of the predicted values). Medications (eg, short-acting inhaled beta-agonist) and equipment for the treatment of severe bronchospasm should be readily available. </b>Use with caution in patients with conditions that may increase sensitivity to bronchoconstriction (eg, severe cough, ventilatory impairment, spirometry-induced bronchoconstriction, hemoptysis of unknown origin, pneumothorax, recent abdominal, thoracic, or intraocular surgery, unstable angina, active upper or lower respiratory tract infection). Patients who have ≥10% reduction in FEV<sub>1</sub> on administration of the 0 mg capsule, patients with a positive response to bronchial challenge testing, or patients who develop significant respiratory symptoms should receive short acting inhaled beta-agonist; monitor until full recovery to baseline. Bronchial challenge testing should not be performed in children &lt;6 years of age as these patients are unable to provide reliable spirometric results.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>- Bronchitol:</b> Use may cause severe bronchospasm; perform the Bronchitol tolerance test prior to use under the supervision of trained professionals. Do not use in patients who fail the Bronchitol tolerance test; patients who pass the tolerance test may still experience bronchospasm with maintenance use and should premedicate with inhaled short-acting bronchodilators. If bronchospasm occurs, discontinue use immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemoptysis: May occur with use; use with caution in patients with history of significant hemoptysis episodes (volume &gt;60 mL); discontinue if hemoptysis occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Drug is primarily renally eliminated and systemic exposure may be increased; use with caution in patient with renal impairment.</p></div>
<div class="block foc drugH1Div" id="F53669404"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bronchitol: 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bronchitol Tolerance Test: 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aridol: Graduated dose; 0 mg (1), 5 mg (1), 10 mg (1), 20 mg (1), 40 mg (15)</p></div>
<div class="block geq drugH1Div" id="F28661995"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54962667"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Bronchitol Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $7.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Bronchitol Tolerance Test Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $7.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Aridol Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0 &amp; 5 &amp; 10 &amp;20 &amp; 40 MG (per each): $7.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54882625"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aridol: Graduated dose; 0 mg (1), 5 mg (1), 10 mg (1), 20 mg (1), 40 mg (15)</p></div>
<div class="block admp drugH1Div" id="F52614607"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral inhalation: For oral inhalation only via inhaler; do not swallow capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">Aridol: Administer using supplied single patient use inhaler; do not puncture capsule more than once; do not swallow capsules. A nose clip may be used if preferred. The patient should exhale completely, followed by a controlled rapid deep inspiration from the device; hold breath for 5 seconds and exhale through the mouth. Measure FEV<sub>1</sub> in duplicate 60 seconds after inhalation; repeat process until positive response or full dose (635 mg) has been administered.</p>
<p style="text-indent:-2em;margin-left:2em;">Bronchitol: <b>Note:</b> Only use in patients who have passed the Bronchitol tolerance test (BTT) (see manufacturer's labeling for more detailed information).</p>
<p style="text-indent:-2em;margin-left:4em;">Prior to a mannitol dose, administer a bronchodilator 5 to 15 minutes before. Administer mannitol morning and night (2 to 3 hours before bedtime) doses using the supplied inhaler. Place 1 capsule in inhaler chamber; turn mouthpiece until it locks in place; push both buttons on side at same time and release. Exhale fully (do not exhale into inhaler), then close lips around mouthpiece and take a steady deep breath inhaling the powder; hold breath for 5 seconds before exhaling. Open inhaler to see if any powder is left in capsule; repeat inhalation process if powder is still left; if empty throw capsule away. Repeat process to complete the total dose (400 mg) of 10 capsules. Discard and replace inhaler after 7 days of use. May wash inhaler if needed; allow to thoroughly air dry before next use. Refer to manufacturer's labeling for more detailed information.</p></div>
<div class="block adm drugH1Div" id="F28662044"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral inhalation:</b> For oral inhalation only; do not swallow capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Aridol</b>: Administer using supplied single patient use inhaler; do not puncture capsule more than once. A nose clip may be used if preferred. The patient should exhale completely, followed by a controlled rapid deep inspiration from the device; hold breath for 5 seconds and exhale through the mouth. Measure FEV<sub>1</sub> in duplicate 60 seconds after inhalation; repeat process until positive response or full dose (635 mg) has been administered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchitol</b>: Prior to initial use, perform the Bronchitol tolerance test (BTT) (see manufacturer's labeling for more detailed information). For patients who have passed the BTT, administer morning and night (2 to 3 hours before bedtime) doses using the supplied inhaler 5 to 15 minutes after administering a short-acting bronchodilator. Place 1 capsule in inhaler chamber; turn mouthpiece until it locks in place; push both buttons on side at same time and release. Exhale fully, then close lips around mouthpiece and take a steady deep breath; hold breath for 5 seconds before exhaling (do not exhale into inhaler). Open inhaler to see if any powder is left in capsule; repeat inhalation process if powder is still left; if empty, throw capsule away. Discard and replace inhaler after 7 days of use. May wash inhaler if needed; allow to thoroughly air dry before next use. Refer to manufacturer's labeling for more detailed information.</p></div>
<div class="block sts drugH1Div" id="F28662023"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Powder for inhalation: Store Aridol at &lt;25°C (&lt;77°F) or Bronchitol between 20°C and 25°C (68°F and 77°F); excursions for both products permitted between 15°C to 30°C (59°F to 86°F). Do not refrigerate or freeze. The Bronchitol inhaler should be discarded and replaced after 7 days of use.</p></div>
<div class="block usep drugH1Div" id="F53571265"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Aridol: Assessment of bronchial hyper-responsiveness (FDA approved in ages ≥6 years and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Aridol is not a standalone test or a screening test for asthma; bronchial challenge testing with mannitol should be used only as part of an overall assessment of asthma.</p>
<p style="text-indent:-2em;margin-left:2em;">Bronchitol: Add-on maintenance therapy to improve pulmonary function in patients with cystic fibrosis (CF) in patients who have passed a Bronchitol tolerance test (FDA approved in ages ≥18 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F28662018"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F28662015"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F28662005"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53571261"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Aridol: Standard spirometry prior to bronchial challenge test; FEV<sub>1</sub> in duplicate 60 seconds after administration of each step of test.</p>
<p style="text-indent:-2em;margin-left:2em;">Bronchitol: Standard spirometry prior to tolerance test. SpO2 and FEV<sub>1</sub> monitoring is required during administration of Bronchitol tolerance test; during therapy, monitor for bronchospasm and hemoptysis (patients with a history of hemoptysis).</p></div>
<div class="block pha drugH1Div" id="F28662026"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The mechanisms of bronchoconstriction to assess hyperresponsiveness or in improving pulmonary function in cystic fibrosis patients are unknown.</p></div>
<div class="block phk drugH1Div" id="F28662028"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 34.3 L (based on IV administration)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Minimally hepatic to glycogen</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Inhaled: 59% (relative to oral administration: 96%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal:  4.7 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: Inhaled: 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~55% to 87% as unchanged drug) </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F46971570"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aridol | Bronchitol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Osmohale</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aridol | Bronchitol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aridol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Osmohale</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aridol | Bronchitol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bronchitol pharmaxis</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aridol | Bronchitol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Axatol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Aridol (mannitol) [prescribing information]. Coral Springs, FL: Methapharm Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  Bronchitol (mannitol) [prescribing information]. Cary, NC: Chiesi USA Inc; October 2020.</div>
</li>
<li>
<div class="reference">
                  Bronchitol (mannitol) [product information]. Frenchs Forest, NSW, Australia: Pharmaxis Ltd; October 2015.</div>
</li>
<li>
<div class="reference">
                  De Boeck K, Haarman E, Hull J, et al. Inhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial. <i>J Cyst Fibros</i>. 2017;16(3):380-387.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-oral-inhalation-pediatric-drug-information/abstract-text/28258928/pubmed" id="28258928" target="_blank">28258928</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. <i>Clinical Practice Guidelines</i>. National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. <a href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" target="_blank">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a>
</div>
</li>
<li>
<div class="reference">
                  Leuppi JD, Brannan JD, Anderson SD. Bronchial Provocation Tests: The Rationale for Using Inhaled Mannitol as a Test for Airway Hyperresponsiveness. <i>Swiss Med Wkly</i>. 2002;132(13-14):151-158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-oral-inhalation-pediatric-drug-information/abstract-text/12070787/pubmed" id="12070787" target="_blank">12070787</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 109306 Version 55.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
